GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (OSTO:BIOSGN) » Definitions » Institutional Ownership

Biosergen AB (OSTO:BIOSGN) Institutional Ownership : 0.02% (As of Apr. 13, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biosergen AB's institutional ownership is 0.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biosergen AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biosergen AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Biosergen AB Institutional Ownership Historical Data

The historical data trend for Biosergen AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosergen AB Institutional Ownership Chart

Biosergen AB Historical Data

The historical data trend for Biosergen AB can be seen below:

2024-05-31 2024-06-30 2024-07-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 0.01 0.01 0.01 0.02 0.02 0.03 0.02 0.02 0.02 0.02

Biosergen AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Biosergen AB Business Description

Traded in Other Exchanges
N/A
Address
Fogdevreten 2, Solna, SWE, 17165
Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.

Biosergen AB Headlines

No Headlines